Skip to content
Review

The emerging landscape of circulatory biomarkers in Alzheimer's disease.

2026 · International review of neurobiology · Vol 191, pp. 275-343 · 0 citations
Medicine

TL;DR

This chapter explores the pathophysiology of Alzheimer's Disease to identify peripheral molecular markers associated with these early events and facilitate the development of combinatorial therapies.

View source

Similar papers

Review 2026

Circulating biochemical signatures of neurodegeneration in Alzheimer's disease.

The blood-based biomarkers represent a transformative step toward early diagnosis, large-scale screening, and precision medicine in AD, with significant potential for the development of disease-modifying therapies.

Greata Rubavathi Eliazer, Mahesh Kandasamy · 0 citations
Review 2026

The clinical utility of blood-based biomarkers of Alzheimer's disease: Triumphs and pitfalls.

This chapter examines the clinical utility of key blood-based biomarkers, including phosphorylated tau, amyloid-β ratios, neurofilament light chain, and glial fibrillary acidic protein, within the context of current diagnostic frameworks.

M. M. Mir, Gulzar Muzaffar Mir, Abdul Majid et al. · 0 citations
Review Open access Aug 2026

Translating blood-based biomarkers into Alzheimer’s disease clinical practice: screening, diagnosis, and longitudinal monitoring

A review of recent advances in BBMs through the ATN-I framework explores how integrating BBMs with traditional cerebrospinal fluid and neuroimaging tests may support symptom-driven clinical triage, probability refinement, and early evaluation in selected individuals, improving clinical workflow efficiency and accessibi...

B. Xie, Wang Zhang, Yu Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.